Similar articles

• Interactions between mesolimbic dopamine neurons, cholecystokinin, and neurotensin: evidence using in vivo voltammetry.

  Phillips AG, Blaha CD, Fibiger HC, Lane RF. Phillips AG, et al. Ann N Y Acad Sci. 1988;537:347-61. doi: 10.1111/j.1749-6632.1988.tb42119.x. Ann N Y Acad Sci. 1988. PMID: 3059931 Review. No abstract available.
• Modulation of mesolimbic dopaminergic behaviors by cholecystokinin.

  Crawley JN. Crawley JN. Ann N Y Acad Sci. 1988;537:380-96. doi: 10.1111/j.1749-6632.1988.tb42121.x. Ann N Y Acad Sci. 1988. PMID: 3059933 Review. No abstract available.
• Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.

  Crawley JN, Hommer DW, Skirboll LR. Crawley JN, et al. Brain Res. 1985 Jun 3;335(2):337-41. doi: 10.1016/0006-8993(85)90489-5. Brain Res. 1985. PMID: 4005562
• Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons.

  White FJ, Wang RY. White FJ, et al. Brain Res. 1984 May 21;300(1):161-6. doi: 10.1016/0006-8993(84)91352-0. Brain Res. 1984. PMID: 6145498
• Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function.

  Vaccarino FJ, Rankin J. Vaccarino FJ, et al. Behav Neurosci. 1989 Aug;103(4):831-6. Behav Neurosci. 1989. PMID: 2765186